In the ADMIRAL trial for patients with R/R FLT3-mutated AML, single-agent gilteritinib was found to significantly improve the median OS from 5.6 to 9.3 months compared with the conventional care regimen. This evidence concerns the gene FLT3 and acute myeloid leukemia.